Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: A phase 1 dose escalation and expansion monotherapy study.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Maria M. Rubinstein, Manish R. Sharma, Kyriakos P. Papadopoulos, Maria-Pilar Barretina-Ginesta, Carmen García-Duran, Mariano Ponz-Sarvise, Andres Redondo, Victor Moreno, Denise S. Uyar, Julian Wampfler, Dagmar Hess, Luis Manso, Jeannette Fuchs, Emmelyne Dessein Corne, Noemie Luong, Vito Dozio, Tri Tat, Francoise Crevel, Victor Rodriguez Freixinos, Anastasios Stathis
Institutions: Memorial Sloan Kettering Cancer Center, South Texas Accelerated Research Therapeutics, Universitat de Girona, Institut Català d'Oncologia, Vall d'Hebron Hospital Universitari, Spanish Ovarian Cancer Research Group, Vall d'Hebron Institute of Oncology, Clinica Universidad de Navarra, Universidad de Navarra, Hospital Universitario La Paz, Hospital Universitario Fundación Jiménez Díaz, Medical College of Wisconsin, University of Bern, Hospital Universitario 12 De Octubre, Debiopharm (Switzerland), Istituto Oncologico della Svizzera Italiana
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410822525